Intra-arterial Delivery of Tislelizumab plus Transarterial Chemoembolization for Rectal Cancer: A Novel Regimen to Achieve Sphincter Preservation and Prevent Anastomotic Leakage

References

[1] D. Li, X. Xiong, P. Diao, et al., “The Review of Modified Intersphincteric Resection in the Treatment of Ultra-Low Rectal Cancer,” Current Treatment Options in Oncology 26, no. 2 (2025): 84-91.

[2] G. Sun, Z. Lou, H. Zhang, et al., “Retrospective Study of the Functional and Oncological Outcomes of Conformal Sphincter Preservation Operation in the Treatment of Very Low Rectal Cancer,” Techniques in Coloproctology 24 (2020): 1025-1034.

[3] J. M. Michael-Robinson, A. Biemer-Hüttmann, D. M. Purdie, et al., “Tumour Infiltrating Lymphocytes and Apoptosis Are Independent Features in Colorectal Cancer Stratified According to Microsatellite Instability Status,” Gut 48, no. 3 (2001): 360-366.

[4] D. T. Le, J. N. Durham, K. N. Smith, et al., “Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade,” Science 357, no. 6349 (2017): 409-413.

[5] F. Xia, Y. Wang, H. Wang, et al., “Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH),” Journal of Clinical Oncology (2024): Jco2302261.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.